Highlights of This Issue 2919

SPECIAL FEATURES

CCR New Strategies

2921 New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
Hans Prenen, Sabine Tejpar, and Eric Van Cutsem

2925 Molecular Pathways

CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Beverly A. Teicher and Simon P. Fricker

CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Beverly A. Teicher and Simon P. Fricker

Control of Tumorigenesis and Chemoresistance by the DEK Oncogene
Erica Riveiro-Falkenbach and María S. Soengas

HUMAN CANCER BIOLOGY

The Proapoptotic Molecule BLID Interacts with Bcl-XL, and Its Downregulation in Breast Cancer Correlates with Poor Disease-Free and Overall Survival
Constantinos G. Broustas, Jeffrey S. Ross, Qifeng Yang, Christine E. Sheehan, Rebecca Riggins, Anne-Michelle Noone, Bassem R. Haddad, Françoise Seiller-Moiseiwitsch, Bhaskar V.S. Kallakury, Bruce G. Haffty, Robert Clarke, and Usha N. Kasid

The Tumor Suppressor UCHL1 Forms a Complex with p53/MM2/ARF to Promote p53 Signaling and Is Frequently Silenced in Nasopharyngeal Carcinoma
Lili Li, Qian Tao, Hongchuan Jin, Andrew van Hasselt, Fan Fong Poon, Xian Wang, Mu-Sheng Zeng, Wei-Hua Jia, Yi-Xin Zeng, Anthony T.C. Chan, and Ya Cao

CANCER THERAPY: PRECLINICAL

The Transcriptional Coregulator RIP140 Represses E2F1 Activity and Discriminates Breast Cancer Subtypes
Aurélie Docquier, Pierre-Olivier Harmand, Samuel Fritsch, Maia Channion, Jean-Marie Darbon, and Vincent Cavailles

Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q- Neuroblastoma

Telomere Maintenance and DNA Damage Responses during Lung Carcinogenesis
Sylvie Lantuejoul, Christophe Raynaud, Dimitri Salameire, Sylvie Gazzetti, Denis Moro-Sibilot, Jean-Charles Soria, Christian Brambilla, and Elizabeth Brambilla

Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line-Derived Human Colorectal Cancer Xenograft Models
John J. Tentler, Erica L. Bradshaw-Pierce, Natalie J. Sankova, Kendra M. Hasebroock, Todd M. Pitts, Jennifer R. Diamond, Graham C. Fletcher, Mark R. Bray, and S. Gail Eckhardt

Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer
IMAGING, DIAGNOSIS, PROGNOSIS

3011 Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle-Invasive Bladder Cancer
Tahlita C.M. Zuiverloon, Madelon N.M. van der Aa, Theo H. van der Kwast, Ewout W. Steyerberg, Hester F. Lingma, Chris H. Bangma, and Ellen C. Zwarthoff

3044 Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

CANCER THERAPY: CLINICAL

3019 A Phase I Study of 5-Fluorouracil/Leucovorin and Arsenic Trioxide for Patients with Refractory/Relapsed Colorectal Carcinoma
Bach Ardalan, Pochi R. Subbarayan, Yipsel Ramos, Michael Gonzalez, Anthony Fernandez, Dmitry Mezentsev, Isildinha Reis, Robert Duncan, Lisa Podolsky, Kelvin Lee, Mayra Lima, and Parvin Ganjeti-Azar

3047 A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Andrew J. Armstrong, George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia A. Cree, Kelly Mundy, S. Lindsay Davis, Ting Wang, Roula Albadine, Luciana Schultz, Alan W. Partin, Antonio Jimeno, Helen Fedor, Phillip G. Febbo, Daniel J. George, Robin Gurganus, Angelo M. De Marzo, and Michael A. Carducci

3028 Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Tanya B. Dorff, Bryan Goldman, Jacek K. Pinski, Philip C. Mack, Primo N. Lara, Jr., Peter J. Van Veldhuizen, Jr., David I. Quinn, Nicholas J. Vogelzang, Ian M. Thompson, Jr., and Maha H.A. Hussain

3057 Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers
Kevin J. Harrington, Eleni M. Karapanagiotou, Victoria Roulostone, Katie R. Twigger, Christine L. White, Laura Vidal, Debbie Reine, Robin Prestwich, Kate Newbold, Merina Ahmed, Khin Thway, Christopher M. Nutting, Matt Coffey, Dean Harris, Richard G. Vile, Hardev S. Pandha, Johann S. DeBono, and Alan A. Melcher

3035 Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
Petri Nokisalmi, Sari Pesonen, Sophie Escutenaire, Merja Särköja, Mari Raki, Vincenzo Cerullo, Leena Laasonen, Ramon Alemany, Juan Rojas, Manel Cascallo, Kilian Guse, Maria Rajeczi, Lotta Kangasniemi, Elina Haavisto, Aila Karioja-Kallio, Paivi Hannukosela, Minna Oksanen, Anna Kanerva, Timo Joensuu, Laura Abstiainen, and Akseli Hemminki

3078 A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer
ABOUT THE COVER

BLID expression was found to be lost or decreased in several invasive ductal breast carcinomas (IDC). The cover image shows an example of BLID-negative IDC as determined by immunohistochemistry using a breast tumor tissue microarray. Lack of BLID was associated with poor prognostic factors and survival. For details, see the article by Broustas and colleagues on page 2939 of this issue.